Common Contracts

19,772,727 Shares GALENA BIOPHARMA, INC. Common Stock and Warrants to Purchase up to 11,863,636 Shares of Common Stock UNDERWRITING AGREEMENT

Galena Biopharma, Inc. • January 7th, 2016 • Pharmaceutical preparations • New York

• Company
  Galena Biopharma, Inc.
• Filed
  January 7th, 2016
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Galena Biopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 19,772,727 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) and (ii) warrants to purchase 11,863,636 shares of Common Stock on the terms and conditions set forth in the Warrant Agreement (as defined herein) (the “Firm Warrants”, and together with the Firm Shares, the “Firm Securities”). All of the Firm Securities are to be issued and sold by the Company. The respective amounts of the Firm Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional (i) 2,965

Aastrom Biosciences, Inc. 46,154,000 Shares of Common Stock Class A Warrants to Purchase 34,615,500 Shares of Common Stock Class B Warrants to Purchase 23,077,000 Shares of Common Stock UNDERWRITING AGREEMENT

Aastrom Biosciences Inc • January 15th, 2010 • Biological products, (no disgnostic substances) • New York

• Company
  Aastrom Biosciences Inc
• Filed
  January 15th, 2010
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

Aastrom Biosciences, Inc., a Michigan corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to issue and sell to you (the “Underwriter”) an aggregate of (i) 46,154,000 shares (the “Firm Shares”) of common stock, no par value per share (the “Common Stock”), (ii) Class A warrants to purchase 34,615,500 shares of Common Stock (the “Firm Class A Warrants”) and (iii) Class B warrants to purchase 23,077,000 shares of Common Stock (the “Firm Class B Warrants”, and together with the Firm Class A Warrants, the “Firm Warrants” and the Firm Warrants collectively with the Firm Shares, the “Firm Securities”). In addition, the Company proposes to grant to the Underwriter an option to purchase (i) up to an additional 6,923,100 shares of Common Stock (the “Option Shares”) and/or (ii) Class A warrants to purchase up to an additional 5,192,325 shares of Common Stock (the “Option Class A Warrants”) and/or (iii) Class B warrants to purchase up to an additional 3,461,